Ergoloid mesylate API Manufacturers
compare suppliers & get competitive offers
Date | Seller | Exporter country | Buyer | Importer country | Product | Quantity (KG) | Price per KG | Latest transactions |
|---|---|---|---|---|---|---|---|---|
| 18-Jul-2024 | (Hidden) | 
Australia
| APOTHECA C... | 
Philippines
| 1 5 G 0860... | 0.01 | $ @36$-7! | Check all data |
| 02-Feb-2024 | (Hidden) |
Australia
| APOTHECA C... |
Philippines
| 1 5KG 0860... | 0.01 | $ @36$-7! |
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ergoloid mesylate API 8067-24-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ergoloid mesylate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ergoloid mesylate
- Synonyms:
- co-dergocrine mesilate , co-dergocrine mesylate , co-dergocrine methanesulfonate , codergocrine mesilate , codergocrine mesylate , Dihydroergotoxine Mesilate , Dihydroergotoxine Mesylate , dihydroergotoxine methanesulfonate , Dihydroergotoxine Methanesulfonate , dihydroergotoxine methanesulfonates , dihydrogenated ergot alkaloids , Ergoloid Mesylates , ergoloid methanesulfonate , ergoloid methanesulfonates , hydrogenated ergot alkaloids
- Cas Number:
- 8067-24-1
- DrugBank number:
- DB01049
- Unique Ingredient Identifier:
- X3S33EX3KW
About Ergoloid mesylate
Here, you can find what Ergoloid mesylate is used for, in short. Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine. The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives.
The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 1953, but this specific formulation is now discontinued.Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. To know more about the individual components of the ergoloid mixture, please visit Epicriptine, Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.
Ergoloid mesylate is a type of Vasoactive agents
Vasoactive agents are a crucial subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a significant role in the treatment of various medical conditions. These agents exert their therapeutic effects by directly influencing the tone and constriction of blood vessels.
Vasoactive agents are commonly utilized in the management of cardiovascular disorders, such as hypertension, heart failure, and angina. They help regulate blood pressure, improve blood flow, and enhance oxygen supply to vital organs. This category includes vasodilators and vasoconstrictors.
Vasodilators work by relaxing the smooth muscles in the blood vessel walls, leading to the widening (dilation) of blood vessels. This relaxation reduces vascular resistance, thereby enhancing blood flow. Examples of vasodilators include nitroglycerin, hydralazine, and calcium channel blockers.
On the other hand, vasoconstrictors act by constricting blood vessels, resulting in increased vascular resistance. These agents are commonly employed in the management of hypotension and shock, where the goal is to maintain blood pressure and restore organ perfusion. Well-known vasoconstrictors include norepinephrine, phenylephrine, and vasopressin.
Vasoactive agents exhibit diverse mechanisms of action and are available in various dosage forms, including tablets, injections, and patches. The appropriate choice of a vasoactive agent depends on the specific medical condition and the patient's individual characteristics.
In conclusion, vasoactive agents are a vital subcategory of pharmaceutical APIs that effectively modulate blood vessel tone. Their therapeutic benefits in cardiovascular conditions make them essential tools for healthcare professionals, ensuring improved patient outcomes and enhanced quality of life.
Ergoloid mesylate (Vasoactive agents ), classified under Others
The others category refers to pharmaceutical APIs that do not fall under specific classifications such as antibiotics, antivirals, analgesics, or cardiovascular drugs. These APIs are diverse in nature and serve various therapeutic purposes, making them a crucial component of pharmaceutical formulations.
Pharmaceutical companies develop APIs in the others category to address specific medical conditions or target novel biological pathways. This category includes APIs used in oncology, neurology, immunology, and other specialized areas of medicine. The APIs in this category are often designed to interact with specific molecular targets or receptors, providing targeted therapeutic effects.
The development of APIs in the others category requires extensive research and testing to ensure their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers employ advanced techniques such as chemical synthesis, biotechnology, and genetic engineering to produce these APIs.
Due to the broad range of applications and therapeutic uses, APIs in the others category contribute significantly to the advancement of medical treatments. Pharmaceutical companies constantly strive to innovate and discover new APIs within this category to address unmet medical needs and improve patient outcomes.
In conclusion, the others category of pharmaceutical APIs encompasses a diverse range of active ingredients used in drug formulation. These APIs play a crucial role in developing innovative therapies across various therapeutic areas, contributing to advancements in healthcare and patient well-being.
